
Global Partners LP (GLP)
$
46.17
-0.25 (-0.54%)
Key metrics
Financial statements
Free cash flow per share
5.8804
Market cap
1.6 Billion
Price to sales ratio
0.0846
Debt to equity
2.3950
Current ratio
1.1406
Income quality
1.7456
Average inventory
513.8 Million
ROE
0.1224
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Global Partners LP is actively engaged in the purchasing, selling, gathering, blending, storing, and logistical transportation of a variety of petroleum products including gasoline, gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, and propane, catering to wholesalers, retailers, and commercial clients throughout the New England states, Mid-Atlantic region, and New York. The company operates a comprehensive Wholesale segment that supplies home heating oil, branded and unbranded gasoline, diesel, kerosene, residual oil, and propane to home heating oil retailers and wholesale distributors. Additionally, it aggregates crude oil via truck or pipeline across the mid-continent region of the United States and Canada, utilizing rail and barge transport to deliver to refiners. Its Gasoline Distribution and Station Operations segment services gasoline station operators and sub-jobbers with both branded and unbranded gasoline while managing networks of gasoline stations and convenience stores that offer car wash, lottery, and ATM services. Within its Commercial segment, the company provides unbranded gasoline, home heating oil, diesel, kerosene, residual oil, and bunker fuel to public sector entities, commercial clients, and industrial users, alongside custom blended fuels. As of December 31, 2021, Global Partners LP held a diverse portfolio consisting of 1,595 owned, leased, and supplied gasoline stations, of which 295 included directly operated convenience stores, and maintained 26 bulk terminals with a total storage capacity of 11.9 million barrels. The EBITDA is $378,785,000.00 a key indicator of the company's operational profitability, and the EBITDA ratio is 0.02 highlighting the company's operational efficiency. The operating expenses amount to $300,344,000.00 encompassing various operational costs incurred, while the weighted average number of diluted shares outstanding is 34,217,000.00 reflecting potential dilution effects. Furthermore, the weighted average number of shares outstanding is 33,871,000.00 highlighting the company's shareholder base. In terms of market positioning, the stock is affordable at $49.24 making it suitable for budget-conscious investors. However, it has a low average trading volume of 46,100.00 indicating lower market activity. With a market capitalization of $1,561,738,987.00 the company is classified as a small-cap player, which is significant in its respective field. It is a key player in the Oil & Gas Midstream industry, contributing significantly to the overall market landscape, and it belongs to the Energy sector, driving innovation and growth. This dynamic positioning within the market underscores the company's potential for future development and influence.
Investing in Global Partners LP (GLP) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Global Partners LP stock to fluctuate between $39.58 (low) and $56.59 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2026-03-24, Global Partners LP's market cap is $1,561,738,987, based on 33,825,839 outstanding shares.
Compared to Exxon Mobil Corporation, Global Partners LP has a Lower Market-Cap, indicating a difference in performance.
Global Partners LP pays dividends. The current dividend yield is 6.50%, with a payout of $0.76 per share.
To buy Global Partners LP (GLP) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for GLP. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Revenue: $18,561,421,000 | EPS: $2.13 | Growth: -13.06%.
Visit https://www.globalp.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $60 (2025-02-21) | All-time low: $19.45 (2021-08-19).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

proactiveinvestors.co.uk
The broker retains its hold rating, warning that overall portfolio growth may stall even as the oral weight-loss pill gains traction Jefferies has trimmed its price target on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant, to DKK270 from DKK275, maintaining a 'hold' rating ahead of first-quarter results. The change came as the broker flagged mounting uncertainty around GLP-1 pricing, oral Wegovy's launch trajectory and the risk that the new pill cannibalises rather than grows the overall franchise.

thenewswire.com
“The window to shape the oral GLP-1 market is open now

seekingalpha.com
General Mills (GIS) is rated a soft buy as its valuation appears attractive after a prolonged decline, despite recent underperformance. GLP-1 appetite-suppressing drugs and rising private label popularity pose headwinds to GIS's revenue and brand strength. GIS's fundamentals show a low TTM GAAP PE of 9.21, strong ~12% net income margins, but concerning 6.5% YOY revenue decline and shrinking EPS.

zacks.com
CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.

fool.com
This gasoline distributor's stock has increased so far in 2026. But how will the current geopolitical tensions threatening oil supply affect its performance?

cnbc.com
For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a GLP-1 drug, like Ozempic or Zepbound, according to the KFF Health Tracking Poll.

proactiveinvestors.co.uk
New trial data complicates the competitive picture in the fast-growing obesity drug market Eli Lilly and Co's (NYSE:LLY) experimental weight-loss and diabetes drug retatrutide has shown a side-effect profile broadly comparable to leading treatments, but new data flagging an unusual skin reaction could give prescribers pause as the race to challenge Novo Nordisk's dominance intensifies. Lilly reported headline results from the first phase three trial of retatrutide in type 2 diabetes, showing patients achieved 16.8% weight loss and a 1.1 percentage point reduction in HbA1c, a standard measure of long-term blood sugar control, after 40 weeks at the 12mg dose.

youtube.com
The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant Shrotriya, managing director at Novo Nordisk India, talks about how generics could reshape the market.

fool.com
Eli Lilly's Mounjaro and Zepbound are the leading drugs in the GLP-1 space. The company's GLP-1 success has resulted in a lofty valuation for the stock.

cnbc.com
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
See all news